Questions About Cancer? 1-800-4-CANCER
  • Print
  • email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Table 3. Comparison of Hematopoietic Stem Cell Products

 PBSCs BM Cord Blood T-cell Depleted BM/PBSCs  Haploidentical T-cell Depleted BM/PBSCs 
T-cell content HighModerateLowVery lowVery low
CD34+ content Moderate–highModerateLow (but higher potency)Moderate–highModerate–high
Time to neutrophil recovery Rapid (13–25 d)Moderate (15–25 d)Slow (16–55 d)Moderate (15–25 d)Moderate (15–25 d)
Early post-HCT risk of infections, EBV-LPD Low–moderateModerateHighVery HighVery High
Risk of graft rejection LowLow–moderateModerate–highModerate–highModerate–high
Time to immune reconstitutiona Rapid (6–12 mo)Moderate (6–18 mo)Slow (6–24 mo)Slow (6–24 mo)Slow (9–24 mo)b
Risk of acute GVHD ModerateModerateModerateLowLow
Risk of chronic GVHD HighModerateLowLowLow

BM = bone marrow; EBV-LPD = Epstein-Barr virus–associated lymphoproliferative disorder; GVHD = graft-versus-host disease; HCT = hematopoietic cell transplantation; PBSCs = peripheral blood stem cells.
aAssuming no development of GVHD. If patients develop GVHD, immune reconstitution is delayed until resolution of the GVHD and discontinuation of immune suppression.
bIf a haploidentical donor is used, longer times to immune reconstitution may occur.